Moderna (MRNA) Investors Face Downturn with a $4.97 Loss on November 2

Moderna (MRNA) Stock Price

On November 2, 2023, Moderna (MRNA) stock closed at $71.23, marking a daily decrease of $4.97, equivalent to a 6.52% decline from the previous day's closing price. The stock experienced notable volatility during the trading session, with the closing price reflecting a significant downturn.

Moderna (MRNA) Stock Analysis

On November 2, 2023, Moderna (MRNA) experienced a significant decline in its stock price on the NASDAQ. The stock opened at $64.35 and faced considerable volatility throughout the trading session, ultimately closing at $71.23. This marked a daily decrease of $4.97, representing a substantial 6.52% drop from the previous day's closing price of $76.20.

Moderna's intraday range was between a low of $62.55 and a high of $73.30. In after-hours trading, MRNA's value stood at $71.01, showing a slight decrease of 0.31% or $0.22. The company's 52-week performance showcased a wide range, with a high of $217.25 and a low of $62.55. Moderna's market capitalization was approximately $27.11 billion, and it boasted a price-to-earnings (P/E) ratio of 26.34, reflecting its presence in the biotechnology and pharmaceutical sectors.

Moderna's stock performance on November 2 was marked by a significant decline, with a closing price of $71.23 and a notable intraday range of $62.55 to $73.30. The after-hours trading showed a marginal decrease, with the stock closing at $71.01. Moderna has experienced substantial fluctuations in its 52-week high and low, with a high point of $217.25 and a low of $62.55, indicating varying investor sentiment over the past year.

The company's market capitalization stood at $27.11 billion, and its P/E ratio was 26.34, underlining its presence in the biotech industry. The decline in stock value on November 2 reflected the evolving dynamics and factors influencing Moderna's performance within the healthcare and pharmaceutical sectors.

Moderna (MRNA) Stock-Key Data

Moderna (MRNA)

Moderna is a pioneering pharmaceutical and biotechnology company headquartered in Cambridge, Massachusetts, renowned for its focus on RNA therapeutics, particularly mRNA vaccines. Their innovative vaccines utilize messenger RNA (mRNA) to instruct the body to produce an immune response. Moderna is most recognized for its groundbreaking Moderna COVID-19 vaccine, marketed as Spikevax, which garnered global attention during the pandemic.

The company's diverse pipeline includes 45 treatment and vaccine candidates, with 38 in clinical trials, spanning a wide range of infectious diseases, cancers, and therapies, reflecting their commitment to advancing the frontiers of modern medicine and biotechnology. Their name, "Moderna," reflects their dedication to modified RNA technology, symbolizing the company's pioneering role in the industry.